What Oncompass Medicine does

Oncompass Medicine (legal entity: Oncompass Medicine Hungary Kft., formerly KPS Diagnosztika) is a precision oncology company founded in 2003 in Budapest, Hungary by Dr. Peták István and Dr. Schwab Richárd. The company operates a molecular diagnostics laboratory that performs next-generation sequencing (NGS), FISH, and IHC analysis of tumor samples to identify actionable mutations across a panel that includes EGFR, BRAF, HER2, ALK/EML4, KRAS, NRAS, MET, PIK3CA, BRCA1/2, KIT, and BCR/ABL. Diagnostic outputs feed the company's flagship product, the Real-Time Oncology Treatment Calculator — an AI-driven clinical decision support system that ranks personalized targeted therapy options by matching patient molecular profiles against a proprietary database of 52,000 mutations, 26,838 medical-biological rules, and 1,417 drug compounds across 405 cancer types, returning ranked treatment suggestions in 20 milliseconds.

The company's core technology stack combines a GS FLX Titanium genome sequencer for laboratory analysis with the proprietary Real-Time Oncology Treatment Calculator software, marketed under the brand name Oncompass Calculator with FISH, IHC, and NGS modules. Patients access services through an online registration portal (app.realtimeoncology.com) and direct consultation; oncologists and cancer treatment centers use the software for clinical decision support. Revenue is generated through per-patient diagnostic testing fees (priced at 50,000 HUF base pathology processing plus 15,000 HUF per gene examined, with EGFR packages at 80,000–95,000 HUF) and through licensing of the decision support software. Distribution leverages partnerships with Affidea Diagnostics (sample collection network), NN Biztosító insurance (payer channel), and Semmelweis University (clinical validation), supported by direct patient engagement and earned media in Hungarian medical and consumer outlets.

Oncompass Medicine has accumulated 3,500+ sequencing reactions and matched 350+ patients with targeted therapies over its operating history. The company held ISO 9001:2015 certification and benefited from EU and Hungarian government R&D funding (NVKP, GINOP programs). It received the DIGITALEUROPE Future Unicorn Award in 2021, the ASCO award in 2019, and multiple Hungarian innovation prizes. In January 2026, the company was acquired by U.S.-based Genomate Health, establishing a European operational base for the acquirer and concluding Oncompass Medicine's independent operating history.

Name

Oncompass Medicine

Legal name

Oncompass Medicine Hungary Kft.

Website

https://molekularis-diagnosztika.hu

Company type

Private

Founded year

2003

Operating status

Acquired

Headcount range

11–50 employees

Short description

Oncompass Medicine is a Hungarian precision oncology company that combines next-generation molecular diagnostic testing with an AI-driven clinical decision support system (Real-Time Oncology Treatment Calculator) to match cancer patients with targeted therapies across 405 cancer types. Founded in 2003 and acquired by Genomate Health in January 2026.

Ownership category

akta.pro rank

Product category

Precision Oncology Diagnostics

NAICS

Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Clinical Decision Support & Workflow Integration (EHR/oncology systems) (HLAAANAE)

Keywords

• Molecular diagnostics
• Precision oncology
• Clinical decision support
• Targeted therapy matching
• Cancer genomic testing

Headquarters

HQ city

Schindellegi

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Molecular Diagnostic Testing Services: Per-patient diagnostic testing fees covering pathology processing and gene sequencing. Revenue generated per test based on number of genes analyzed.
2. Software Licensing: Licensing of Real-Time Oncology Treatment Calculator to healthcare institutions for clinical decision support.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

Oncompass Medicine performs molecular diagnostic testing on tumor samples to identify actionable genetic mutations and operates the proprietary Real-Time Oncology Treatment Calculator, an AI-driven clinical decision support system that matches patient molecular profiles to targeted therapy options across 405 cancer types. Services are delivered through its Budapest laboratory and an online patient portal, supported by partnerships with diagnostic networks and insurance providers.

Product overview

Oncompass Medicine operates a platform-based product portfolio centered on AI-powered precision oncology. The core offering is the Real-Time Oncology Treatment Calculator, an AI decision support system that processes molecular diagnostic data to rank targeted therapy options across 405 cancer types. This platform is supported by laboratory-based Molecular Diagnostic Testing Services that analyze tumor samples for genetic mutations (EGFR, BRAF, HER2, ALK, KRAS, etc.) using FISH, IHC, and NGS modules integrated into the Oncompass Calculator system. The ecosystem is accessible through the Real-time Oncology Patient Portal, enabling patient registration and consultation. Together, these products form an end-to-end precision medicine solution that connects molecular diagnostics with AI-driven treatment recommendations.

Differentiator

Problem solved

Functional benefit

Brands

• Real-Time Oncology Treatment Calculator: A proprietary software system that ranks personalized targeted therapy options across 405 cancer types, 52,000 mutations, based on 26,838 medical-biological rules and 1,417 drug active ingredients.
• Oncompass Calculator

Products and services

• Real-Time Oncology Treatment Calculator AI-powered oncology decision support system that ranks personalized targeted therapy options by analyzing molecular diagnostic data against 26,838 medical-biological rules across 405 cancer types, 52,000 mutations, and 1,417 drug substances in 20 milliseconds. Licensed to healthcare institutions for clinical decision support.
• Molecular Diagnostic Testing Services Laboratory-based genetic testing of tumor samples analyzing mutations including EGFR, BRAF, HER2, ALK/EML4, KIT, KRAS, NRAS, BCR/ABL, BRCA1/2, PIK3CA, MET, and others to identify targetable mutations for personalized cancer treatment.
• Oncompass Calculator with FISH, IHC and NGS Modules Medical IT decision support software integrated with molecular diagnostic laboratory modules including Fluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC), and Next-Generation Sequencing (NGS) capabilities for comprehensive cancer molecular profiling.
• Real-time Oncology Patient Portal Online patient registration and consultation platform enabling cancer patients to access molecular diagnostic services, schedule consultations, and connect with healthcare providers for personalized treatment recommendations.

Quantifiable outcome

• 3,500+ sequencing reactions completed
• +1 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Genomate HealthcoreStrategic or Co-development Partner · 14 January 2026Strategic acquisition of Genomate Health to expand molecular diagnostic capabilities and market presence in the precision oncology space.
• Affidea DiagnosticscoreChannel Partner/ Reseller/ DistributorPartnership with Affidea diagnostic centers providing patient access points for molecular testing across Hungary. Affidea operates a network of diagnostic facilities that serve as patient touchpoints for Oncompass Medicine services.
• NN BiztosítóminorGTM or Marketing PartnerInsurance partnership agreement with NN Biztosító enabling coverage of molecular diagnostic testing for the company's insurance policyholders.
• Semmelweis Egyetem (Semmelweis University)coreStrategic or Co-development PartnerStrategic cooperation agreement with Hungary's leading medical university for clinical validation, research collaboration, and academic validation of molecular diagnostic methodologies.
• Innovációs és Technológiai Minisztérium (ITM) - Ministry of Innovation and TechnologycoreStrategic or Co-development PartnerStrategic cooperation with Hungarian government ministry supporting innovation in healthcare technology and precision medicine research.
• ADMONT ConsortiumminorStrategic or Co-development PartnerEuropean innovation cooperation project participation as part of the ADMONT consortium focused on advanced medical technology development.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Foundation Medicine: Roche-owned leader in comprehensive genomic profiling for oncology; competes head-on with Oncompass's molecular diagnostic testing services but at much larger scale across the US and globally.
• Guardant Health: US-listed leader in liquid biopsy and oncology molecular profiling with a growing treatment-matching data platform; comparable molecular diagnostics + clinical interpretation offering.
• Tempus Labs: Large-scale precision medicine platform combining molecular sequencing, clinical decision support, and data analytics in oncology; comparable end-to-end platform play but with substantially larger data assets and funding.
• NeoGenomics: Large US oncology-focused clinical laboratory providing molecular and genetic testing services with growing bioinformatics capabilities; overlaps with Oncompass's molecular testing business at greater scale.
• 2bPrecise (Quest Diagnostics): Precision oncology decision support platform from Quest Diagnostics delivering EHR-integrated genomic insights to oncologists; comparable clinical decision support + oncology workflow integration offering.

Direct peers

• Molecular Health: Germany-headquartered precision oncology company offering molecular data analysis and treatment decision support, closely mirroring Oncompass's combination of molecular profiling with AI-driven therapy matching.
• SOPHiA Genetics: Switzerland-headquartered AI-driven genomics and clinical decision support company serving European hospitals; similar European geographic profile and SaaS-style decision support model.
• Caris Life Sciences: US-based molecular profiling and AI-driven precision oncology company offering both molecular diagnostics and treatment recommendation platforms, directly comparable to Oncompass's dual service + software offering.
• Personalis: US-based cancer genomics company providing tumor profiling combined with clinical interpretation tools for therapy selection; directly comparable molecular diagnostics + decision support model.
• Genomate Health: US-based precision medicine company that acquired Oncompass in January 2026; uses computational reasoning for cancer care, making it both the new parent and the closest functional peer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncompass Medicine